This is further supported by conflicting reports in cancer, as increased IL-32 levels associate with enhanced anti-tumor immunity and good patient prognosis in cutaneous melanoma (5) but tumor progression in many epithelial cancers (6, 7). This evidence concerns the gene IL32 and neoplasm.